Loading…
← CockpitCompetitor Analysis › 300584.SZ Nanjing Hicin Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Nanjing Hicin Pharmaceutical Co., Ltd. Class A300584.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum neutral 46
Mkt cap
$487M
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$27.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+5.7 pp
WACC 5.0%
Hurdle
+4 pp
Req g minus delivered
Close · CNYCN¥27.50
1D-2.8%
1W-14.4%
1M-2.4%
3M-21.7%
6M-28.7%
YTD-45.2%
1Y-50.8%
ATR %5.6%
52w lowhigh62.5% off high

What Nanjing Hicin Pharmaceutical does

Employees: 553

Nanjing Hicin Pharmaceutical at a glance

Size Nanjing Hicin Pharmaceutical (300584.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $487M, the 3762nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥27.50 on 18 Nov 2026.

Performance Over six months the shares fell 28.7%, against -13.3% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 32.4% over the last twelve months (peer median +11.2%); the operating margin is 17.5% (peer median 8.4%).

Valuation It trades at 4.3× enterprise value to sales against a peer median of 3.9× (10th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.7 points above its cost of capital (5.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 86300584.SZ 73
Six months, rebased to 100: Nanjing Hicin Pharmaceutical against the median of its 20 peers (local-currency closes).

Nanjing Hicin Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥815MCN¥661MCN¥498MCN¥511MCN¥521M
Revenue growth—+33%-3%-2%—
Gross profitCN¥607MCN¥499MCN¥376MCN¥381MCN¥363M
EBITDAn/aCN¥142MCN¥96.0MCN¥97.0MCN¥82.3M
Net incomeCN¥71.6MCN¥42.1MCN¥40.2MCN¥36.3MCN¥32.4M
Free cash flowCN¥5.44MCN¥15.4M-CN¥18.0M-CN¥173M-CN¥225M
Capital expenditureCN¥28.9MCN¥62.6MCN¥77.9MCN¥197MCN¥219M
Total debtCN¥324MCN¥288MCN¥315MCN¥299MCN¥226M

Quarterly statements and history in the cockpit →

Nanjing Hicin Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%0030203012771666688373002107RGNXAARTIDRUGSHNSA003090600513TKNO600624SMSPHARMA600222AQSTGYRE3705301201GUJTHEM300584.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Nanjing Hicin Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×10×20×0030203012771666688373002107AARTIDRUGSHNSA003090600513TKNO600624SMSPHARMA600222AQST301201GUJTHEM300584.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nanjing Hicin Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%3012771666002107AARTIDRUGSHNSA6002223705300584.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nanjing Hicin Pharmaceutical is the large dot.

Nanjing Hicin Pharmaceutical competitors and peer comparison

How Nanjing Hicin Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nanjing Hicin Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300584.SZPeer medianRank in peer set
1-month return-2.4%-3.9%10th highest of 21
6-month return-28.7%-13.3%3rd lowest of 21
Distance from 52-week high-62.5%-35.5%3rd lowest of 21
Revenue growth (TTM)+32.4%+11.2%2nd highest of 21
Operating margin17.5%8.4%4th highest of 21
EV / Sales4.3×3.9×10th most expensive of 21
Growth the price implies (Req g, 7 yrs)3.3%1.0%5th least demanding of 9
Growth delivered (Del g)-1.1%+5.3%2nd lowest of 9
Hurdle (Req g minus delivered)+4.3 pp-2.4 pp4th most demanding of 9
ROIC minus cost of capital+5.7 pp-3.0 pp3rd highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a

Questions

Which companies are Nanjing Hicin Pharmaceutical's closest peers?
The cockpit's peer set: Hefei Lifeon Pharmaceutical (003020.SZ), Newland Pharmaceutical (301277.SZ), Tong Ren Tang Technologies (1666.HK), Shanghai MicuRx Pharmaceutical (688373.SS), Shandong Wohua Pharmaceutical (002107.SZ), REGENXBIO (RGNX), Aarti Drugs (AARTIDRUGS.NS), Hansa Biopharma (HNSA.ST).
Is Nanjing Hicin Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 4.3× against a peer median of 3.9×, 10th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Nanjing Hicin Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -28.7% against -13.3% for the median peer; over one year -50.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.